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Abstract: 
Until very recently, understanding the complexity of the stem cell compartment in both normal and 
leukemic hematopoiesis has been challenging due to the inability to separate and study normal and 
leukemic stem cells at the single-cell level. Recent advances in cell sorting techniques and single-cell 
technologies now make this possible, with the identification of a population of highly quiescent 
chronic myeloid leukemia stem cells that are enriched following therapy with tyrosine kinase 
inhibitors (73 words). 
 
Main text:  
The introduction of BCR-ABL tyrosine kinase inhibitors (TKI) has revolutionized management of 
chronic myeloid leukemia (CML) [1]. However, in CML, areas of unmet clinical need remain 
progression to aggressive advanced phase CML, resistance to multiple TKIs in chronic phase and low-
level disease persistence which results in relapse on cessation of therapy [2]. Despite a molecularly 
targeted therapeutic approach, there remains a rare cohort of cells, termed leukemic stem cells, 
which are selectively resistant to TKI therapy and incompletely eradicated in most patients [1]. These 
LSCs are responsible for disease relapse post treatment discontinuation [2], and reside in the same 
microenvironment as their normal hematopoietic stem cell (HSC) counterparts, expressing the same 
CD34+CD38- phenotype [3].  
A better understanding of stem cell (SC) heterogeneity in CML will help devise new strategies to 
eradicate these cells and improve patient outcomes. To date, research has used “bulk” samples of 
unfractionated stem and progenitor cells. These samples likely contain a mixture of normal and 
leukemic cells, with different leukemic sub-clones and different levels of cell maturation. Recent 
advances in single-cell transcriptomic technologies have enabled researchers to study clonal 
evolution in different tumors [4, 5] including leukemia [6]. Recent work from Giustacchini et al. [7] 
characterizes distinct molecular signatures of SC subpopulations in CML from diagnosis through 
remission and disease progression (Figure 1).  
The hallmark of CML is the presence of BCR-ABL fusion oncogene. As current single-cell RNA 
sequencing approaches, including Smart-seq2 [8], are not sensitive enough to consistently detect 
this fusion gene, Giustacchini et al. developed a BCR-ABL-targeted Smart-seq2 protocol (BCR-ABL 
tSs2). This approach enabled BCR-ABL detection with no evidence of bias in library quality and a 
strong correlation of RefSeq genes generated by Smart-seq2 or BCR-ABL tSS2 in CML cells. 
Comparison of BCR-ABL+ and BCR-ABL- SCs from a CML patient identified differentially expressed 
genes and a strong correlation (P=0.87) was seen between single-cell RNA sequencing and qPCR 
data. Thus, the BCR-ABL tSs2 protocol allows sensitive and quantitative BCR-ABL detection with 
unbiased whole-transcriptome analysis. 
 Giustacchini et al. analysed SC data from 20 patients with CP-CML, and found BCR-ABL- SCs to be 
similar to normal HSCs in terms of number of genes detected, and expression patterns of genes 
involved in proliferation and quiescence (Figure 1.1). Contrastingly, BCR-ABL+ SCs had a significantly 
higher number of reads detected compared to healthy normal donor HSCs and BCR-ABL- SCs from 
CML patients; with a bias towards genes involved in proliferation and reduced quiescence-associated 
expression. Irrespective of patient profile, distinct clusters of normal HSCs, BCR-ABL+ and BCR-ABL- 
SCs were seen on t-distributed stochastic neighbour embedding (tSNE) analysis, a machine learning 
algorithm for dimentionality reduction, particularly suited to single-cell analyses [9]. The authors 
observed differential expression of genes previously implicated in CML pathogenesis, and identified 
several novel candidate genes that were differentially expressed between normal HSCs, BCR-ABL+ 
and BCR-ABL- SCs. Gene set enrichment analysis (GSEA) identified several gene sets enriched in BCR-
ABL+ SCs; none of which would have been identified through in silico bulk cell analysis. Given the 
importance of the tumor microenvironment, the authors also identified gene sets enriched in the 
BCR-ABL- SCs compared to normal HSCs, including those involved in IL6, TGFβ and TNFα pathways. 
In further experiments by Giustacchini et al., patient samples were stratified into good or poor 
responders to TKI. GSEA on diagnostic samples showed enrichment of signalling pathways, 
inflammation, TGF-β and TNF-α-associated genes in BCR-ABL+ and BCR-ABL- SCs from poor compared 
with good responders. In contrast, both BCR-ABL+ SCs and BCR-ABL- SCs from good responders 
showed an enrichment of genes associated with increased proliferation such as E2F, MYC and G2M-
checkpoint. These findings suggest that BCR-ABL+ and BCR-ABL- SCs from poorly-responding patients 
have enrichment of genes involved in quiescence, including TGF-β and TNF-α-associated genes, and 
this may be a mechanism of TKI resistance.  
Single-cell sequencing of BCR-ABL+ and BCR-ABL- SCs was performed on paired patient bone marrow 
samples from diagnosis and following 3-6 months TKI therapy (Figure 1.2). Following TKI, fewer BCR-
ABL+ SCs were present, and BCR-ABL+ and BCR-ABL- SCs had a similar average number of genes 
detected per cell. tSNE analysis revealed two distinct clusters of remission BCR-ABL+ SCs; one 
enriched for quiescence and HSC-associated genes (group-A) and a second enriched for 
proliferation-associated genes (group-B). Group-A expressing cells were enriched with prolonged TKI 
treatment, indicating selective persistence of distinct and highly quiescent BCR-ABL+ SCs (group-A) 
which are already present at diagnosis, rather than development of resistant CML-SCs, or stochastic 
persistence of heterogeneous CML-SCs. Further analyses demonstrated that, compared to normal 
HSCs, group-A BCR-ABL+ SCs showed enrichment of Wnt/ β-catenin, TGF-β, TNF-α and IL-6-JAK-STAT-
associated gene expression, while normal HSCs were enriched for MYC, E2F and G2M-checkpoint-
associated genes. This single-cell transcriptomic analysis provides insights into pathways that are 
potentially involved in promoting selective persistence of distinct BCR-ABL+ SCs following TKI 
treatment, and include quiescence and inflammation. 
In separate experiments, tSNE analysis of blast crisis (BC)-CML-SCs from 3 patients demonstrated a 
separate cluster of BCR-ABL+ SCs (Figure 1.3), clearly distinct from normal HSC, BCR-ABL+ SCs from 18 
patients with CP-CML and K562 cells. Two of the patients had progressed to BC-CML on TKI and had 
samples from diagnosis, presenting in CP, 12 and 3 months before transformation. One of the two 
patients developed lymphoid BC, and a minority of pre-BC SCs from that patient cluster with BCR-
ABL+ CP-CML-SCs. This demonstrates evolution from CP- to BC-CML within the SC compartment prior 
to any clinical or morphological evidence of BC. Further, exome sequencing of this patient’s sample 
revealed a somatic RUNX1 mutation and differential regulation of RUNX1 target genes between the 
pre-BC, CP-CML-SC and BC-CML-SC clusters, consistent with the acquisition of RUNX1 mutation as a 
genomic event occurring pre-BC and driving BC transformation.  
To conclude, single-cell gene expression approaches have tremendous potential to enhance our 
understanding of biological diversity and rare cell types. Giustacchini et al. used CML as the 
paradigm disease model, as the LSC compartment is well established and the persistence of rare 
CML-SCs remains a key therapeutic challenge [1]. Single-cell transcriptomics were used to unravel 
LSC heterogeneity, and reveal insights that may help to predict and understand SC persistence in 
responding and disease progression in poorly-responding patients.  
This novel single-cell approach to investigating cellular heterogeneity is an attractive avenue across 
not just other malignancies, particularly cancer stem cell disorders, or analysis of heterogeneity of 
circulating tumor cells (a relatively non-invasive approach), but also other areas of clinical interest, 
including studying virus-host interactions and neuronal transcriptional profiles in response to stimuli. 
This technology when backed with a robust computational pipeline and/or modelling has the 
potential to change our perspective of many diseases.  
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Figure 1 legend. 
Title: Exploring stem cell heterogeneity in chronic myeloid leukemia. 
Single cells were FACS-sorted as Lin-CD34+38- from bone marrow samples of normal donors and CML 
patients. BCR-ABL tSs2 protocol was used to create single-cell cDNA libraries.  
1) tSNE visualization of single normal HSCs (black circles), BCR-ABL- SCs (blue pentagons) and BCR-
ABL+ SCs (red triangles) shows distinct clustering of the 3 groups. Marked dysregulation of TGF-β and 
TNF-α pathways in BCR-ABL+ SCs in patients with CML, associated with increase SC quiescence.  
2) tSNE visualization of single normal HSCs (black circles), BCR-ABL+ SCs from patients at diagnosis 
(grey triangles) and BCR-ABL+ SCs from patients at remission: group A (blue diamonds) and group-B 
(red hexagons). Group-A BCR-ABL+ SCs showed enrichment of TGF-β, TNF-α and IL-6 – JAK – STAT 
associated gene expression compared to normal HSCs or BCR-ABL- SCs. Group-A remission CML-SCs 
are characterized by marked quiescence-associated gene expression, selectively evading TKI 
eradication. Group-B remission CML-SCs showed enrichment of MYC, E2F and proliferation-
associated gene sets and cluster with diagnostic BCR-ABL+ SCs.  
3) tSNE visualization from normal HSCs (black circles), CP-CML patients (yellow triangles) and BC-
CML patients (green diamonds). Distinct clusters of normal HSCs, CP-CML and BC CML were 
observed; the authors also noticed a minority of pre-BC SCs from one patient to cluster with CP-CML 
SCs predicting imminent disease progression in cancer SC populations.  
FACS; fluorescence activated cell sorting, CML; chronic myeloid leukemia, tSNE; t-distributed 
stochastic neighbour embedding, HSC; hematopoietic stem cells, SCs; stem cells, CP; chronic phase, 
BC; blast crisis. 
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